Adjuvant Chemotherapy May Be New Standard of Care for Upper Tract Urothelial Cancer
The median follow-up was 17.6 months at time of interim analysis.
Genitourinary (GU) Cancers Symposium
Pembrolizumab Improves OS, ORR After 2 Years vs Chemotherapy in Urothelial Cancer
Of 542 enrolled patients, 270 were randomly assigned to pembrolizumab and 272 were assigned to chemotherapy. All patients progressed after platinum therapy.
Enzalutamide Reduces Risk of Metastasis in Castration-Resistant Prostate Cancer
Researchers randomly assigned 1401 men with M0 CRPC undergoing ADT to receive enzalutamide 160 mg or placebo.
Prostate Cancer: Adding Zoledronate to Androgen Suppression and Radiotherapy Not Beneficial
A significant reduction in prostate cancer-specific mortality — the primary outcome — was observed among patients who received 18 months of AS.
Comparing Daily vs Weekly Image-Guided Radiotherapy for Prostate Cancer
It is unestablished whether daily or weekly IGRT is optimal for patients with N0 localized prostate cancer.
Genomic Alterations in Metastatic Renal Cell Carcinoma
Patients with metastatic renal carcinoma (mRCC) treated with post-frontline agents had increased genomic alterations.
Adjuvant BEP for 1 Cycle Safe, Efficacious for Testicular Cancer
Bleomycin, etoposide, and cisplatin (BEP) for 1 cycle after orchiectomy is associated with a similar 2-year recurrence rate as BEP.
Pembrolizumab Improves Survival and Quality of Life in Advanced Bladder Cancer
Pembrolizumab following platinum-based chemotherapy was associated with significantly longer overall survival, fewer adverse events.
Bladder Cancer: Genomics May Predict Benefit from Neoadjuvant Chemotherapy
David J. McConkey, MD, PhD, described how genomics can affect the clinical management of patients with bladder cancer.
Urothelial Carcinoma: Year in Review
Studies presented in the last year demonstrated a revolutionary role for immune checkpoint inhibitors.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Genitourinary Cancers Symposium 2017
Loading... 
Loading...